Shares in the penny stock of Palatin Technologies Inc. (NYSE Amex: PTN) is now covered by analysts at Roth Capital with a “buy” rating. Palatin, a biopharmaceutical company dedicated to developing targeted, receptor-specific peptide therapeutics, has seen a significant drop in revenues compared to 2010 but could be looking at a rebound in the short-term.
Six weeks ago, Palatin announced that over 400 premenopausal women, diagnosed with female ...
Continue Reading →
24
APR
APR
0
Share
One of the rare penny stocks on the New York Stock Exchange Rite Aid Corp. (